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Mantle cell lymphoma (MCL) is nowadays recog-nized as a spectrum of diseases, characterized bysignificantly different treatment responses and
outcomes. Some predictors of clinical and biological out-
come have been established and validated over recent
years, and these are either assessable at baseline (mainly
MCL international prognostic indexes, Ki-67 proliferative
index and genomic aberrations) or during treatment (func-
tional imaging and minimal residual disease, MRD). MRD
is defined as the minimal traceable persistence of lym-
phoma cells after a successful treatment. Many methods
to monitor MRD have been published; however, the most
sensitive and the most commonly used and best standard-
ized approach in MCL is represented by the allele-specific
oligonucleotide (ASO) quantitative polymerase chain reac-
tion (qPCR) method.1 The most relevant prospective trials
investigating the impact of MRD on MCL patient out-
come are listed in Table 1A.
The clinical role of MRD analysis in MCL is reflected
according to four major aspects (Figure 1).
MRD provides early feedback on the efficacy of the clearance
of different induction regimens. The dynamics and stability of
tumor shrinkage after treatment can currently be precisely
tracked by MRD kinetics; these data might be useful as an
early in vivo predictor of the anti-lymphoma effect of a
new compound.6,9,10 Moreover, MRD can be used as a sur-
rogate end point for progression-free survival (PFS) com-
paring the efficacy of different treatments in randomized
trials, thus accelerating the development, and eventually
the approval, of new drugs. For example, the superior out-
come of the cytarabine-containing experimental arm of
the “MCL Younger” phase III trial of the European MCL
Network was heralded by a higher rate of MRD clearance
many years before publication of the final results.5,15
MRD can provide an early prediction of disease recurrence.
Even in the context of an incurable disease like MCL, the
deepness of treatment response measured by MRD wide-
ly reflects patient outcome in large, prospective trials.3-5
The predictive role of MRD analysis in MCL was con-
firmed in different patient subsets (both younger and eld-
erly), treatment strategies (autologous transplantation and
conventional immuno-chemotherapy), tissues (bone mar-
row and peripheral blood) and time points (end of induc-
tion and during maintenance treatment).4
MRD allows for risk stratification of patients after treatment.
MRD describes the efficacy of therapy and presence of even
minimal, resistant tumor clones; thus, this approach identi-
fies patients at higher risk of recurrence after an apparently
successful treatment. Actually, persistence of MRD positiv-
ity or recurrence after a transient MRD negativity precedes
clinical relapse, with a median time lag of 18 months.16
MRD might drive pre-emptive treatment.As MRD positivity
predicts upcoming clinical relapse, this approach can guide
treatment tailoring, with the aim of preventing or delaying
overt disease progression. In a number of prospective
reports, a pre-emptive rituximab treatment of MRD posi-
tive patients was able to reconvert them to MRD negativ-
ity, with the possibility of also prolonging their PFS.8,17
Nevertheless, some limitations still hamper the wide-
spread use of MRD analysis in clinical routine. The two
major obstacles as far as methodology is concerned are the
need for patient-specific primers and standardization
issues. At present, the ASO-qPCR strategy relies upon
either the clonal rearrangement of the IGH gene or the
BCL-1/IGH rearrangement, derived from the t(11;14);
both of these DNA sequences are unique for each B-cell
clone, so individual primers are required for each patient
to guarantee a reliable sensitivity. Thus a “one-fits-all”
easy-to-use in vitro diagnostic medical device (IVD-kit) is
not conceivable in MRD diagnostics so far, and access to
an experienced and dedicated laboratory is mandatory. In
addition, a rigorous standardization of the methods is
essential in order to provide comparable results among dif-
ferent centers. Only selected laboratories across Europe
have so far been certified by the Euro MRD consortium, a
standardization group regularly performing quality control
rounds for MRD analysis in leukemia and lymphoma
(http://www.euromrd.org).18 Only by standardized analyses
in this laboratory network can reliable MRD results be
obtained in large, international clinical trials, such as the
Table 1A. Prospective clinical trials investigating the impact of minimal residual disease (MRD) on patients' outcome in mantle cell lymphoma (MCL) patients.
Study Study population Study features Marker,  Evaluable Sample analyzed Study treatment MRD evaluation 
method patients or MRD impact on outcome
Pott, 20062 MCL, <70 y Local protocol IgH, qPCR 29 BM, PB, harvest R-HDS +TBI PFS 92 vs. 21 m 
and  GLSG + ASCT (P<0.001)
Prospective trial BCL1, IgH, N-PCR 79 PB, BM R-maxiCHOP/R- PFS NR vs. 18 m 
Geisler, 20083 MCL <66 y phase II, HD-AraC + ASCT + (P<0.001)
non-randomized in vivo purging
Pott, 20104 MCL, younger Phase III, BCL1, IgH, qPCR 190 BM, PB, harvest R-CHOP +TBI + PFS 77% vs. 34% 
and elderly randomized ASCT vs. R-CHOP/R-DHAP at 2 y FU
+ R-HD-AraC +TBI (P=0.021)
+ ASCT  (younger);
R-FC vs. R-CHOP (elderly)
Hermine, 20165 MCL, <65 y Phase III, Unspecified, qPCR 497 PB, BM R-CHOP +TBI + HD CTX EOI MRD neg: 47% 
randomized + ASCT vs. R-CHOP/R-DHAP vs. 79%
+ AraC +TBI + Mel + ASCT  (PB), 26% vs.
61% (BM)
Albertsson-Lindblad, MCL, elderly Phase I-II BCL1, IgH, N-PCR 51 PB, BM Len-BR x6 + Len EOI MRD neg: 32%
20176 maintenance
Liu, 20127 MCL, <69 y Phase II, BCL1, IgH, qPCR 39 PB, BM R-HD-MTX TTP at 3 y 82%
non-randomized + maxi-CHOP + ASCT vs. 48% (MRD at EOI)
+ R maintenance
Kolstad, 20168 MCL, <66 y Phase II, BCL1, IgH, N-PCR 183 BM  R-maxiCHOP PFS 20 m vs. 142 m
non-randomized + ASCT ± RIT (MRD post-ASCT); median OS
NR vs. 35 m 
Visco, 20169 MCL, elderly Phase II BCL1, IgH, N-PCR 57 PB, BM R-BAC500 No association between
MRD status and PFS
Zaja, 201710 MCL, >18 y Phase II, BCL1, IgH, N-PCR, qPCR 42 PB, BM R2B + R2 36% of MRD negativization,
non-randomized consolidation + predictive of PFS
Len maintenance
Armand, 201611 MCL, transplant Phase II, IgH, NGS 23 PB, plasma BR + R-HD-ARA-C 93% MRD neg at EOT
eligible (42-69 y) non-randomized
Callanan, 201512 MCL, <66 y Phase III, IgH, qPCR 178 PB, BM R-DHAP MRD status pre-ASCT
randomized +R-BEAM-ASCT  in  BM and PB predicts
± R maintenance longer PFS 
(P=0.0451, P=0.0016)
Gressin, 201413 MCL, elderly Phase II, IgH, qPCR 76 PB, BM RiBVD MRD neg: 83% (PB)
non-randomized and 74% (BM) at 6 months 
Kaplan, 201514 MCL, <70 y Phase II, BCL1, IgH, unspecified 151 Not available augCHOP+MTX+EAR+ 5-y PFS: 93% if MRD-neg
randomized CBV-ASCT+ bortezomib vs. 51% if MRD-pos 
maintenance vs. consolidation following induction 
therapy
Table 1B. Current MRD-driven trials in MCL. 
Clinicaltrials.gov Short title Patients' Study features Estimated enrollment Study treatment Primary outcome
identifier characteristics (n. of patients)
02354313 FIL_MCL0208 MCL , <65 y Phase III, 300 R-CHOP + HD-CTX + HD- PFS
randomized Ara-C + BEAM and ASCT 
± lenalidomide maintenance
02896582 LyMa 101 MCL, <65 y Phase II, 83 GA-DHAP + GA-BEAM + MRD negativity at 
single-arm ASCT + GA maintenance end of induction  
Not available EA4151 - MCL, transplant eligible Phase III, 689 induction therapy ± ASCT + OS 
ECOG group randomized R maintenance 
MCL: mantle cell lymphoma;  R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; TBI: total body irradiation; ASCT: autologous stem cell transplant; Mel: melphalan;
EOI: end of induction; B-R: bendamustine, rituximab; Len: lenalidomide; R-DHAP: rituximab, cytarabine, dexamethasone, cisplatin; R-BAC500: rituximab, bendamustine,  cytarabine; EOT: end of treat-
ment; GLSG: German Lymphoma Study Group; HD-CTX: high-dose cyclophosphamide; HD-Ara-C: high-dose cytarabine; RIC: reduced intensity conditioning; HD-CHT: high-dose chemotherapy; RIT:
radio-immunotherapy; RiBVD: rituximab, bendamustine bortezomib and dexamethasone; y: years; m: months; BM: bone marrow; PB: peripheral blood; vs.: versus; neg.: negative; pos: positive; PFS:
progression-free survival; OS: overall survival.
Editorials
1134 haematologica | 2017; 102(7)
recently launched TRIANGLE trial (EudraCT n. 2014-
001363-12), sponsored by the European MCL Network.
Moreover, another limitation of the current technique is
that 10-15% of patients still lack a reliable molecular
marker for MRD. For the moment, in MCL, an IGH-based
marker is available in approximately 70% of cases and a
BCL-1/IGH marker in approximately 35-40%, with some
overlapping cases.4 In particular, patients with low or
absent bone marrow invasion often do not carry a marker
and cannot, therefore, be analyzed for MRD. In addition,
hypermutated IGH genes may hamper an optimal primer
design. Finally, although the predictive role of MRD has
been established in MCL,3-5 evidence for the usefulness of
subsequent treatment tailoring based on the MRD results
is unfortunately still scarce due to the lack of MRD-driven
phase III trials in MCL.8,17 Moreover, no MRD data are
available yet in the context of the new targeted treat-
ments, such as the Bruton’s tyrosine kinase inhibitor ibru-
tinib.
However, many technical innovations have recently been
introduced in the MRD field, and these have the potential
to overcome the issues of applicability and sensitivity
described above. The droplet digital PCR (ddPCR), a 3rd-
generation, end point, quantitative PCR has been shown to
provide comparable results to ASO-qPCR for MRD moni-
toring in MCL with the advantage that it is less labor inten-
sive. Moreover, since it does not require a standard curve
for tumor quantification, ddPCR might provide reliable and
sensitive MRD results also in cases in which the classical
approach has failed.19 Currently, a totally innovative
approach is represented by the application of next-genera-
tion sequencing (NGS) techniques to the MRD field. The
LymphoSIGHTTM approach was first published for MRD
detection in acute lymphoblastic leukemia,20 and was sub-
sequently shown to be feasible also in MCL.21 Its main
advantages rely on the fact that it does not require patient-
specific reagents (being thus suitable for an IVD-kit), it can
provide additional MRD targets for patients lacking a “clas-
sical” molecular marker, it should easily reach high sensitiv-
ity levels, and might overcome some false-negative results
(e.g. deciphering the clonal evolution issues). However,
until now, this promising NGS technology has been avail-
able as a commercial tool only in US. Nevertheless, many
laboratories are currently implementing alternative NGS-
based approaches for MRD and an international develop-
ment and standardization effort is ongoing within the
EuroClonality-NGS laboratory consortium (http://www.euro-
clonality.org/wp-content/uploads/2015/03/EuroClonality-
NGS.pdf).22 Moreover, further promising NGS-based
approaches for the identification of new molecular mark-
ers are being studied and might effectively provide an
MRD target for each patient in the near future (Targeted
Locus Amplification and Rapid Capture techniques).23,24
Finally, MRD targeting on plasmatic, circulating tumor
DNA is extremely promising as a means to track lym-
phoma clones residing outside the peripheral blood or
bone marrow compartments.25 Despite all of these encour-
aging data, a large-scale validation of each of these new
technologies is required before their introduction into clin-
ical practice.
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Figure 1. The clinical role of minimal residual disease analysis in mantle cell lymphoma.
Nowadays, MRD evaluation is mostly based on ASO-
qPCR in the most important ongoing European clinical tri-
als and, as explorative investigation, as part of clinical rou-
tine in a few selected centers. However, for the moment,
the published diagnostic and treatment guidelines discour-
age any clinical decision-making based on MRD results,26
mainly due to limitations of technical standardization and
to the lack of prospective, randomized trials evaluating
modified therapy according to MRD. Reliable and repro-
ducible MRD data can currently be guaranteed only by the
standardized methodological guidelines of the Euro MRD
laboratory network. Therapeutic decisions based on MRD
results obtained by different, as yet not validated tech-
niques may even compromise the patient’s long-term out-
come. Moreover, convincing data on the real usefulness of
such an MRD-based treatment modulation are not yet
available in lymphoma, with only retrospective evidence
or evidence derived from a single, phase II trial available so
far.8,17 Some MRD-driven phase II and III trials are ongoing
in MCL and also in follicular lymphoma to assess the clin-
ical impact of personalized treatment, with first results
eagerly awaited in the near future (reviewed by Dogliotti
and Ferrero27 and summarized for MCL in Table 1B).
In conclusion, given that there is compelling evidence as
to the predictive role of MRD in MCL, and ongoing stan-
dardization and methodological efforts are highly
advanced, MRD analysis in MCL is already included in the
majority of prospective trials. The next steps will consist of
large trials investigating an MRD-driven tailored therapeu-
tic approach (Table 1B). Thanks to the expected results and
the development of rapidly evolving MRD techniques, we
foresee that, in the near future, the huge research efforts
over the last years will finally translate into personalized
treatment strategies as part of clinical routine, leading to a
further benefit for lymphoma patients in general.
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